SCHEMBL3010896

SCHEMBL3010896

Cc1cc(C)c(-c2csc(N3CCC(S(=O)(=O)c4ccc(F)cc4Cl)CC3)n2)c(C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 5/20 0.48
MAPK1 P28482 2/20 0.41
SMN1; SMN2 Q16637 6/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
ALDH1A1 P00352 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
AR P10275 4/20 0.39
MAPT P10636 4/20 0.38
LMNA P02545 2/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
RECQL P46063 1/20 0.38
HSD17B10 Q99714 1/20 0.38
HTT P42858 2/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006066 0.93 CTSS (0.52) CTSSMAPK1SMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL3007684 0.91 MAPK1 (0.42) CTSSMAPK1SMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL3014807 0.91 AR (0.43) CTSSMAPK1SMN1; SMN2ALDH1A1NPC1
SCHEMBL3016387 0.90 CTSS (0.49) CTSSMAPK1SMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL3001264 0.90 MAPK1 (0.43) MAPK1SMN1; SMN2L3MBTL1ALDH1A1NPC1
SCHEMBL3012067 0.89 SMN1; SMN2 (0.40) CTSSMAPK1SMN1; SMN2ALDH1A1NPC1
SCHEMBL3014430 0.88 SMN1; SMN2 (0.52) CTSSMAPK1SMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL3005439 0.88 CTSS (0.45) CTSSMAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL3008278 0.87 AR (0.53) CTSSMAPK1SMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL3011275 0.87 CTSS (0.51) CTSSMAPK1SMN1; SMN2L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CTSS 106/4885MAPK1 2767/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.